5:28 PM
 | 
Jan 28, 2013
 |  BC Extra  |  Clinical News

Active Biotech's Anyara misses RCC endpoint

Active Biotech AB (SSE:ACTI) fell SEK7.50 (13%) to SEK51.50 on Monday after it said Anyara naptumomab estafenatox plus interferon (IFN) alpha missed the primary endpoint of improving overall survival (OS) vs. IFN alone in a European Phase II/III...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >